CN1130203C - 阿凡曼菌素和米尔倍霉素的注射剂 - Google Patents
阿凡曼菌素和米尔倍霉素的注射剂 Download PDFInfo
- Publication number
- CN1130203C CN1130203C CN97198028A CN97198028A CN1130203C CN 1130203 C CN1130203 C CN 1130203C CN 97198028 A CN97198028 A CN 97198028A CN 97198028 A CN97198028 A CN 97198028A CN 1130203 C CN1130203 C CN 1130203C
- Authority
- CN
- China
- Prior art keywords
- avermectins
- benzyl alcohol
- reactive compound
- oleum
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000005660 Abamectin Substances 0.000 title claims abstract description 40
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 title claims abstract description 15
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 title abstract 2
- 239000007972 injectable composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000011877 solvent mixture Substances 0.000 claims abstract description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 18
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 14
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 14
- 229960002418 ivermectin Drugs 0.000 claims description 14
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 11
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 10
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 8
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 8
- 229940093471 ethyl oleate Drugs 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 10
- -1 fatty acid esters Chemical class 0.000 abstract description 9
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 150000001241 acetals Chemical class 0.000 abstract description 2
- 125000001931 aliphatic group Chemical group 0.000 abstract description 2
- 235000019438 castor oil Nutrition 0.000 abstract description 2
- 239000004359 castor oil Substances 0.000 abstract description 2
- 150000005676 cyclic carbonates Chemical class 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 8
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 6
- 229960004217 benzyl alcohol Drugs 0.000 description 6
- 235000013773 glyceryl triacetate Nutrition 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 229960002622 triacetin Drugs 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 229950008167 abamectin Drugs 0.000 description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 3
- 235000010388 propyl gallate Nutrition 0.000 description 3
- 239000000473 propyl gallate Substances 0.000 description 3
- 229940075579 propyl gallate Drugs 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 2
- 229960003997 doramectin Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940074076 glycerol formal Drugs 0.000 description 2
- 229960004816 moxidectin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DBDJCJKVEBFXHG-UHFFFAOYSA-N L-Oleandrose Natural products COC1CC(O)OC(C)C1O DBDJCJKVEBFXHG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DBDJCJKVEBFXHG-BNHYGAARSA-N Oleandrose Natural products O(C)[C@H]1[C@H](O)[C@H](C)O[C@H](O)C1 DBDJCJKVEBFXHG-BNHYGAARSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940000188 cydectin Drugs 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- GOYBREOSJSERKM-ACZMJKKPSA-N oleandrose Chemical compound O=CC[C@H](OC)[C@@H](O)[C@H](C)O GOYBREOSJSERKM-ACZMJKKPSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及基于含有芝麻油、中等链长甘油三酯、二醇酯或脂肪酸酯和一种其他选自单-或多羟基脂肪族或芳族醇和它们的衍生物(例如环状碳酸酯、乙酸酯、缩醛、缩酮)或蓖麻油的溶剂的溶剂混合物的阿凡曼菌素和米尔倍霉素的注射剂。
Description
技术领域
本发明涉及新的基于含芝麻油的溶剂混合物的阿凡曼菌素和米尔倍霉素的注射剂。
背景技术
异阿凡曼菌素的注射剂被揭示于EP-A-146414中。该制剂含有比率为60∶40v/v的丙二醇和环亚甲基甘油醚的溶剂混合物。人们已经知道，某些浓度的丙二醇可以引起局部无法忍受(参见综述：B.Kruss，Acta Pharm.Technol.35(4)(1989)187-196)。在给药部位附近的组织中也会发生水不溶性活性化合物异阿凡曼菌素的沉淀。因此，当使用相应的制剂时，在注射部位观察到明显肿胀和组织不相容，这种状况有时经过数周之后仍然存在。
具体的阿凡曼菌素注射剂被揭示于EP-A-393890中。它们是基于比率为90∶10v/v的芝麻油和油酸乙酯的油制剂。这些制剂是可以耐受的，但是它们有缺陷，即阿凡曼菌素/米尔倍霉素的溶解性不足使得通常不能够获得使用时需要的1％m/v或更高的浓度。通常，在高温条件下(T≥80℃)获得过饱和的1％m/v溶液，其在较低温度下又持续结晶出来。
阿凡曼菌素的其他注射剂公开在EP-A-45655中。该文献中描述的制剂含有较高量的乳化剂，并在某些情况下不能被很好地耐受。
含有三醋精(甘油三乙酸酯)的阿凡曼菌素注射剂描述在EP-A-413538中。在EP-A-535734中描述了基于三醋精和氢化蓖麻油的阿凡曼菌素注射剂。
米尔倍霉素和阿凡曼菌素的其他注射制剂描述在EP-A-525307中。该制剂通过熔化甘油三硬脂酸酯和活性化合物和与油性天然甘油三酯混合和使用例如甲基纤维素和盐乳化制备。由此得到的微乳液的平均颗粒大小是25-300微米。
发明内容
本发明涉及基于含有芝麻油，中等链长甘油三酯或二醇酯或脂肪酸酯和一种其它溶剂的溶剂混合物的阿凡曼菌素和米尔倍霉素的注射剂。
该制剂优选含有：
1.活性化合物0.2-5％m/v；
2.芝麻油60-90％v/v；
3.中等链长甘油三酯或二醇酯或脂肪酸酯10-30％(体积)；
4.1-20％(体积)的苯甲醇或丙二醇或其他适合的脂肪族或芳族单-或多羟基醇和它们的衍生物(例如环状碳酸酯，乙酸酯，乙缩醛/缩酮)或蓖麻油；5.如果适当的话，其它辅助剂。
本发明的制剂具有明显的对活性化合物的溶解性。
通过加入中等链长甘油三酯或丙二醇辛酸酯/癸酸酯或尤其是油酸乙酯可以将芝麻油的高粘度调节至所需的低粘度。此外，通过加入较小体积的亲水性溶剂如苯甲醇，丙二醇或丙二醇碳酸酯并且保持单相系统，活性化合物的溶解性可以被改善，粘度可以被进一步降低，活性化合物的生物利用度可以被改善。蓖麻油是对涉及的活性化合物具有高溶解力的唯一的甘油三酯。
在本发明的制剂中使用的活性化合物是已知的。
阿凡曼菌素作为微生物的代谢产物从微生物--除虫链霉菌分离得到(US4310519)，并且基本上以A1a，A1b，A2a，A2b，B1a，B1b，B2a，和B2b的八种组分的混合物存在(I.Putter等，Experentia37(1981)第963页，Birkhauser Verlag(Switzerland))。此外，人们对其合成衍生物，特别是22，23-二氢阿凡曼菌素B1(异阿凡曼菌素)也很有兴趣(US4199569)。米尔倍霉素B-41D从吸水链霉菌通过发酵分离得到(参见“米尔倍霉素：发现和开发”I.Junya等，Annu.Rep.Sankyo Res.Lab.45(1993)，第1-98页；日本专利8378549；GB1390336)。
将阿凡曼菌素类，例如22，23-二氢阿凡曼菌素B1(异阿凡曼菌素)和米尔倍霉素用作杀内寄生虫药早已为人所知，并且是许多专利申请和论文综述的主题(例如，有关生物学效果方面：“Ivermectinand Abamectin”W.C.Campbell，Ed.，Springer Verlag，New York，N.Y.，1989；“阿凡曼菌素和米尔倍霉素类，第II部分”，H.G.Davieset al.Chem.Soc.Rev.20(1991)pp271-339；有关化学修饰方面：G.Lukacs et al.(Eds).Springer-Verlag，New York，(1990)，第三章；Cydectin[Moxidectin and derivatives]：G.T.Carter et al.《英国化学会志》，化学通报，(1987)，pp.402-404；EP423445A1)。“doramectin-一种新的强力杀内寄生虫药”A.C.Goudie etal.Vet.parasitol.49(1993)，pp5-15)。
可以被特别强调的阿凡曼菌素类及其衍生物是那些具有通式(I)的化合物：其中：基团R1至R4具有下表1中给定的含义，X可以表示C22与C23位置之间的单键或双键(-C22R1-X-C23R2-)。
如果有双键存在，在C22与C23位置没有取代基(R1，R2)。表1
22，23-二氢阿凡曼菌素B1是异阿凡曼菌素；sec-Bu＝仲丁基；iso-Pr＝异丙基；Chx＝环己基；Me＝甲基
| 大环内酯 | -C22R1-X-C23R2- | R3 | R4 |
| 阿凡曼菌素A1a | -CH＝CH- | -sec-Bu | -Me |
| 阿凡曼菌素A1b | -CH＝CH- | -iso-Pr | -Me |
| 阿凡曼菌素A2a | -CH2-CHOH- | -sec-Bu | -Me |
| 阿凡曼菌素A2b | -CH2-CHOH- | -iso-Pr | -Me |
| 阿凡曼菌素B1a | -CH＝CH- | -sec-Bu | -H |
| 阿凡曼菌素B1b | -CH＝CH- | -iso-Pr | -H |
| 阿凡曼菌素B2a | -CH2-CHOH- | -sec-Bu | -H |
| 阿凡曼菌素B2b | -CH2-CHOH- | -iso-Pr | -H |
| 22，23-二氢阿凡曼菌素B1a | -CH2-CH2- | -sec-Bu | -H |
| 22，23-二氢阿凡曼菌素B1b | -CH2-CH2- | -iso-Pr | -H |
| Doramectin | -CH＝CH- | -Chx | -H |
通式(I)的阿凡曼菌素类和22，23-二氢阿凡曼菌素B1(异阿凡曼菌素)通常作为混合物使用。其中特别有意义的是产物阿巴美丁，其含有阿凡曼菌素B1，和它们的氢化产物，22，23-二氢阿凡曼菌素B1(异阿凡曼菌素)。
不必将在C25位置上有一个异丙基团的标有“b”的大环内酯化合物从在C25位置上有仲丁基的“a”化合物中分离。一般是分离到这两种化合物的混合物，其中仲丁基衍生物(B1a)占80％以上，异丙基衍生物(B1b)不足20％，根据本发明可以使用该混合物。另外，在立体异物体情况下，C13和C23位置的取代基会在环上以α和β构型排列，即可能位于分子平面之上或之下。在每种情形下，所有立体异构体都在本发明考虑范围内。
米尔倍霉素类可以被特别地提到。米尔倍霉素类象阿凡曼菌素或22，23-二氢阿凡曼菌素B1(异阿凡曼菌素)那样具有相同的大环内酯环状结构，但在13位没有取代基(即丢失齐墩果糖的双糖片断)(R5＝氢)。
作为来自大环内酯类的米尔倍霉素的实例，可以提及具有通式(II)的化合物：
其中：
基团R1-R5具有下表2中给定的含义：表2
iso-Pr＝异丙基
可以被特别强调的活性化合物是：
阿凡曼菌素B1a/B1b(阿巴美丁)，
22，23-二氢阿凡曼菌素B1a/B1b(异阿凡曼菌素)
doramectin
Moxidectin
本发明制剂中存在的活性化合物的浓度是0.2-5％，优选0.5-2％，特别优选1％m/v。
本发明制剂中采用的芝麻油(60-90％v/v)是已知的。
本发明制剂中采用的粘度降低剂，尤其是油酸乙酯，是已知的。
可以用作注射制剂成分的其他良好溶剂尤其是苯甲醇，丙二醇，环亚甲基甘油醚，丙二醇碳酸酯，三醋精，Myvacete(Eastman的商标)，丙二醇二乙酸酯，聚乙二醇400，四甘醇和蓖麻油。特别优选苯甲醇(1-5％v/v)和蓖麻油(10-20％v/v)。
异阿凡曼菌素在苯甲醇中的溶解度大于40％(重量)，在蓖麻油中的溶解度是约4％(重量)。
用于本发明制剂的其他添加剂是稳定剂如丁基羟基茴香醚(BHA)，丁基羟基甲苯(BHT)或没食子酸丙酯，其总量最高达1000ppm。特别适合的稳定剂组合和浓度是，例如，100ppmBHA或100ppmBHA加150ppm没食子酸丙酯或200ppmBHA加100ppm没食子酸丙酯。
本发明制剂的粘度是20-60mPa.s(20℃)，优选25-55mPa.s(20℃)，特别优选30-51mPa.s(20℃)。
下面的实施例说明本发明。注释：
v/v＝体积/体积相应于体积百分比
m/v＝质量/体积
1％m/v表示，例如，10mg活性化合物在1ml溶液中。
具体实施方式实施例1
芝麻油 足量100％v/v
油酸乙酯 10％v/v
苯甲醇 2％v/v
异阿凡曼菌素 1％m/v
丁基羟基茴香醚(BHA) 100ppm(Δ0.01％m/v)
密度： 0.922g/ml
粘度： 44mPa.s(20℃)
85mPa.s(5℃)
24mPa.8(39℃)
实施例2
芝麻油 足量100％v/v
油酸乙酯 20％v/v
蓖麻油 10％v/v
异阿凡曼菌素 1％m/v
丁基羟基茴香醚(BHA) 100ppm(Δ0.01％m/v)
密度： 0.927g/ml
粘度： 38mPa.s(20℃)
83mPas(5℃)实施例1和2作为无菌注射液的一般制备方法：
将与100ppmBHA一起提供的芝麻油和油酸乙酯称量并且加入不锈钢容器中并且搅拌匀化。将溶于或部分溶于苯甲醇或蓖麻油的异阿凡曼菌素加入并且进一步搅拌。混合物温热至40-60℃以保证活性化合物迅速和完全地溶解(所有操作在氮气充气下进行)。然后将混合物在相同温度下通过0.22微米过滤器(通常预插入0.45微米或1微米过滤器)无菌过滤。然后无菌分散到棕色玻璃瓶中。
当用于家畜时这种方式制备的制剂是明显可忍耐的。此外，它们在60℃温度下贮存至少6周还是稳定的。
Claims (4)
1.具有下列组成的注射制剂：
在溶剂混合物中的0.2-5％m/v的阿凡曼菌素或米尔倍霉素，该溶剂混合物的组成是
60-90％v/v的芝麻油，和
10-30％v/v的油酸乙酯或辛酸/癸酸甘油三酯或丙二醇二辛酸/二癸酸酯和
1-5％v/v苯甲醇或10-20％v/v的蓖麻油
和任选地最多1000ppm的稳定剂。
2.根据权利要求1的注射制剂，其具有下列组成：
1％m/v的异阿凡曼菌素，65-90％v/v的芝麻油，10-20％v/v的油酸乙酯和1-3％v/v的苯甲醇或10％v/v的蓖麻油和任选地最多500ppm的稳定剂。
3.制备权利要求1的注射制剂的方法，其特征在于，将活性化合物溶解于蓖麻油或苯甲醇中并且加入权利要求1中指出的其它成分，或者将活性化合物溶解于权利要求1指出的成分的混合物中。
4.蓖麻油或苯甲醇作为增溶剂在权利要求1的注射制剂中的用途。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19638045.6 | 1996-09-18 | ||
| DE19638045A DE19638045A1 (de) | 1996-09-18 | 1996-09-18 | Injektionsformulierungen von Avermectinen und Milbemycinen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1230890A CN1230890A (zh) | 1999-10-06 |
| CN1130203C true CN1130203C (zh) | 2003-12-10 |
Family
ID=7806009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97198028A Expired - Fee Related CN1130203C (zh) | 1996-09-18 | 1997-09-08 | 阿凡曼菌素和米尔倍霉素的注射剂 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6617314B2 (zh) |
| EP (1) | EP0939638B1 (zh) |
| JP (1) | JP4822196B2 (zh) |
| KR (1) | KR20000035978A (zh) |
| CN (1) | CN1130203C (zh) |
| AR (1) | AR008844A1 (zh) |
| AT (1) | ATE228845T1 (zh) |
| AU (1) | AU750874B2 (zh) |
| BR (2) | BR9712058B1 (zh) |
| CA (1) | CA2265952C (zh) |
| DE (2) | DE19638045A1 (zh) |
| DK (1) | DK0939638T3 (zh) |
| ES (1) | ES2184135T3 (zh) |
| HK (1) | HK1022845A1 (zh) |
| NZ (1) | NZ334673A (zh) |
| PL (1) | PL332137A1 (zh) |
| WO (1) | WO1998011902A1 (zh) |
| ZA (1) | ZA978352B (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| KR20000025762A (ko) * | 1998-10-14 | 2000-05-06 | 유충식 | 이버멕틴류의 가용화 조성물 |
| GB9827727D0 (en) | 1998-12-16 | 1999-02-10 | Pfizer Ltd | Antiparasitic formulations |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| AU781682B2 (en) * | 2000-03-20 | 2005-06-09 | Zoetis Services Llc | Sustained-release compositions for parenteral administration |
| US6872708B2 (en) * | 2001-09-10 | 2005-03-29 | Mitsukazu Matsumoto | Local injection prescription |
| US7396819B2 (en) * | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
| US7582612B2 (en) | 2004-03-12 | 2009-09-01 | Hartz Mountain Corporation | Multi-action anthelmintic formulations |
| US20100022469A1 (en) * | 2008-06-24 | 2010-01-28 | Majid Razzak | Anthelminthic formulations |
| PL2396006T3 (pl) * | 2009-02-16 | 2013-06-28 | Zoetis Llc | Preparat zawierający doramektynę w dużej dawce |
| CN101773467B (zh) * | 2010-01-20 | 2015-09-09 | 北京大北农动物保健科技有限责任公司 | 一种美贝霉素或美贝霉素肟的兽用缓释注射液及制备方法 |
| EP2544721B1 (en) * | 2010-03-09 | 2017-12-06 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| US9616044B2 (en) | 2012-03-13 | 2017-04-11 | Bayer New Zealand Ltd | Long acting compositions |
| CN103417478B (zh) * | 2012-05-18 | 2014-09-10 | 中国农业科学院兰州畜牧与兽药研究所 | 一种以水为基质的伊维菌素o/w型注射液及其制备方法 |
| US20170196802A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long Acting Injectable Formulations |
| US20210137960A1 (en) | 2018-02-01 | 2021-05-13 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
| CN114107097B (zh) * | 2021-11-10 | 2024-03-05 | 河北兴柏农业科技股份有限公司 | 一种阿佛曼链霉菌活性孢子的固体发酵工艺 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ197796A (en) * | 1980-08-04 | 1984-11-09 | Merck & Co Inc | Stabilised aqueous formulations containing ivermectin |
| NZ210505A (en) * | 1983-12-22 | 1988-06-30 | Merck & Co Inc | Parasiticidal compositions containing avermectin or milbemycin derivatives |
| ES2052173T3 (es) * | 1989-04-11 | 1994-07-01 | Pfizer | Composiciones inyectables que contienen 25-cyclohexil-avermectina b1. |
| US6001822A (en) * | 1989-04-11 | 1999-12-14 | Pfizer Inc. | Antiparasitic formulations |
| NZ234802A (en) * | 1989-08-14 | 1992-11-25 | Merck & Co Inc | Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals |
| US5030650A (en) | 1989-09-11 | 1991-07-09 | American Cyanamid Company | 13-halo-23-imino derivatives of LL-F28249 compounds and their use as endo- and ectoparasiticidal, insecticidal, acaricidal and nematocidal agents |
| US5055486A (en) | 1989-12-22 | 1991-10-08 | American Cyanamid Company | 13-alkyl-23-imino derivative of LL-F28249 compounds and their use as endo- and ectoparasiticidal, insecticidal, acaricidal and nematocidal agents |
| DE69208765T2 (de) * | 1991-07-23 | 1996-09-26 | American Cyanamid Co | Stabile Zusammensetzungen für parenterale Verabrechung und ihre Verwendung |
| ATE180671T1 (de) * | 1991-09-30 | 1999-06-15 | Merck & Co Inc | Hydrierte rizinusöl-enthaltende injizierbare formulierungen mit verlängerter wirkstoffabgabe |
| GB2275193A (en) * | 1993-02-17 | 1994-08-24 | Merck & Co Inc | Formulations for the topical delivery of avermectins |
| DE4443888A1 (de) * | 1994-12-09 | 1996-06-13 | Bayer Ag | Dermal applizierbare Formulierungen von Parasitiziden |
| WO1997011709A1 (en) * | 1995-09-25 | 1997-04-03 | Ashmont Holdings Limited | Anthelmintic macrocyclic lactone compositions |
| DE19613972A1 (de) * | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
| RU2140737C1 (ru) * | 1998-09-22 | 1999-11-10 | Мосин Владимир Александрович | Средство для профилактики и лечения паразитарных заболеваний животных |
| CN1219393A (zh) * | 1998-11-13 | 1999-06-16 | 王玉万 | 一种含阿维菌素或伊维菌素的兽用抗寄生虫油剂口服液及其制备方法 |
-
1996
- 1996-09-18 DE DE19638045A patent/DE19638045A1/de not_active Withdrawn
-
1997
- 1997-09-08 CN CN97198028A patent/CN1130203C/zh not_active Expired - Fee Related
- 1997-09-08 KR KR1019997001893A patent/KR20000035978A/ko not_active Application Discontinuation
- 1997-09-08 AU AU46215/97A patent/AU750874B2/en not_active Ceased
- 1997-09-08 US US09/254,615 patent/US6617314B2/en not_active Expired - Lifetime
- 1997-09-08 ES ES97944849T patent/ES2184135T3/es not_active Expired - Lifetime
- 1997-09-08 PL PL97332137A patent/PL332137A1/xx unknown
- 1997-09-08 BR BRPI9712058-8A patent/BR9712058B1/pt not_active IP Right Cessation
- 1997-09-08 NZ NZ334673A patent/NZ334673A/xx not_active IP Right Cessation
- 1997-09-08 EP EP97944849A patent/EP0939638B1/de not_active Expired - Lifetime
- 1997-09-08 DK DK97944849T patent/DK0939638T3/da active
- 1997-09-08 CA CA002265952A patent/CA2265952C/en not_active Expired - Lifetime
- 1997-09-08 AT AT97944849T patent/ATE228845T1/de active
- 1997-09-08 JP JP51423798A patent/JP4822196B2/ja not_active Expired - Fee Related
- 1997-09-08 DE DE59708905T patent/DE59708905D1/de not_active Expired - Lifetime
- 1997-09-08 WO PCT/EP1997/004867 patent/WO1998011902A1/de active IP Right Grant
- 1997-09-08 BR BRPI9715298A patent/BRPI9715298B8/pt active IP Right Grant
- 1997-09-17 ZA ZA9708352A patent/ZA978352B/xx unknown
- 1997-09-18 AR ARP970104297A patent/AR008844A1/es active IP Right Grant
-
2000
- 2000-03-31 HK HK00101987A patent/HK1022845A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9712058A (pt) | 1999-08-24 |
| CA2265952C (en) | 2009-11-17 |
| ZA978352B (en) | 1998-03-24 |
| AU750874B2 (en) | 2002-08-01 |
| US20020160967A1 (en) | 2002-10-31 |
| DE19638045A1 (de) | 1998-03-19 |
| HK1022845A1 (en) | 2000-08-25 |
| ATE228845T1 (de) | 2002-12-15 |
| ES2184135T3 (es) | 2003-04-01 |
| PL332137A1 (en) | 1999-08-30 |
| BR9712058B1 (pt) | 2009-05-05 |
| JP4822196B2 (ja) | 2011-11-24 |
| BRPI9715298B8 (pt) | 2016-04-26 |
| AR008844A1 (es) | 2000-02-23 |
| BR9715298B1 (pt) | 2014-10-14 |
| US6617314B2 (en) | 2003-09-09 |
| EP0939638A1 (de) | 1999-09-08 |
| CA2265952A1 (en) | 1998-03-26 |
| DK0939638T3 (da) | 2003-03-24 |
| CN1230890A (zh) | 1999-10-06 |
| DE59708905D1 (de) | 2003-01-16 |
| EP0939638B1 (de) | 2002-12-04 |
| WO1998011902A1 (de) | 1998-03-26 |
| AU4621597A (en) | 1998-04-14 |
| NZ334673A (en) | 2000-10-27 |
| KR20000035978A (ko) | 2000-06-26 |
| JP2001503029A (ja) | 2001-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1130203C (zh) | 阿凡曼菌素和米尔倍霉素的注射剂 | |
| CN1095662C (zh) | 以蓖麻油为基础的阿凡曼菌素或米尔倍霉素的注射制剂、其制备以及蓖麻油的相关应用 | |
| CN1112924C (zh) | 用于静脉注射的雷怕霉素制剂 | |
| CN1291713C (zh) | 以塔三烷衍生物为主组分的新组合物 | |
| KR101131794B1 (ko) | Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법 | |
| EP0633783A1 (en) | Rapamycin formulation for iv injection | |
| CN1209059A (zh) | 紫杉烷类组合物及方法 | |
| WO2004089239A2 (en) | Topical anthelmintic veterinary formulations | |
| JPH0623100B2 (ja) | 改良された抗寄生虫活性を持つ非水性イベルメクチン処方剤 | |
| US6340671B1 (en) | Stable compositions for parenteral administration and their use | |
| NZ512686A (en) | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents | |
| US20080207670A1 (en) | Dermally Applicable Formulations For Treating Skin Diseases in Animals | |
| EP0650729A1 (en) | Rapamycin formulations for IV injection | |
| CN1568999A (zh) | 稳定的医药用河豚毒素冷冻干燥制剂 | |
| US20040198704A1 (en) | Compositions and method for treating microbial and parasitic infections in cattle and other animals | |
| KR20060113737A (ko) | 약제학적 조성물 | |
| KR102244500B1 (ko) | 서방형 부프레노르핀 제제 | |
| CN1686411A (zh) | 鱼腥草注射用乳剂及其制备方法 | |
| MXPA99002566A (en) | Injectable formulations of avermectins and milbemycins | |
| KR100483912B1 (ko) | 피마자유를기초로한아버멕틴과밀베마이신의주사제제 | |
| AU2809501A (en) | Injection formulations of avermectins and milbemycins | |
| CN1575794A (zh) | 含丙硫咪唑亚砜的液体制剂 | |
| MXPA97007257A (en) | A parasiticide composition injectable long and procedure to prepare | |
| CN1726908A (zh) | 穿琥宁口服乳剂组合物 | |
| KR20110000259A (ko) | 고분자 유화제를 함유하는 안정성이 우수한 면역증강제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BAYER ANIMAL HEALTH PROMOTION CO.,LTD. Free format text: FORMER OWNER: BAYER AG Effective date: 20091106 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091106 Address after: Germany Leverkusen Patentee after: Bayer Animal Health GmbH Address before: Germany Leverkusen Patentee before: Bayer Aktiengesellschaft |
|
| ASS | Succession or assignment of patent right |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER ANIMAL HEALTH GMBH Effective date: 20130123 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130123 Address after: German Monheim Patentee after: Bayer Pharma Aktiengesellschaft Address before: Germany Leverkusen Patentee before: Bayer Animal Health GmbH |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031210 Termination date: 20160908 |